참고문헌
- Baum ES, Gaynon P, Greenberg L, et al (1979). Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children's Cancer Study Group Report. Cancer Treat Rep, 63, 1621-7.
- Bielack SS, Kempf-Bielack B, Delling G, et al (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 20, 776-90. https://doi.org/10.1200/JCO.20.3.776
- Bleyer W (1981). Therapeutic drug monitoring of methotrexate and other antineoplastic drugs. In 'Interpretations in Therapeutic Drug Monitoring', Eds Baer DM, Dita ER. American Society of Clinical Pathology, Chicago pp 169-81.
- Bramwell VH, Burgers M, Sneath R, et al (1992). A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol, 10, 1579-91.
- Bramwell VH, Burgers MV, Souhami RL, et al (1997). A randomized comparison of two short intensive chemotherapy regimens in children and young adults with osteosarcoma: results in patients with metastases: a study of the European Osteosarcoma Intergroup. Sarcoma, 1, 155-60. https://doi.org/10.1080/13577149778245
- Choeyprasert W, Natesirinilkul R, Charoenkwan P, et al (2013). Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. Asian Pac J Cancer Prev, 14, 1101-6. https://doi.org/10.7314/APJCP.2013.14.2.1101
- Cores EP, Holland JF, Wang JJ, et al (1972). Doxorubicin in disseminated osteosarcoma. JAMA, 221, 1132-8. https://doi.org/10.1001/jama.1972.03200230020005
- Coventry MB, Dahlin DC (1957). Osteogenic sarcoma; a critical analysis of 430 cases. J Bone Joint Surg Am, 39, 57-8.
- Dahlin DC (1978). Osteosarcoma of bone and a consideration of prognostic variables. Cancer Treat Rep, 62, 189-92.
- Delepine N, Delepine G, Bacci G, et al (1996). Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer, 78, 2127-35. https://doi.org/10.1002/(SICI)1097-0142(19961115)78:10<2127::AID-CNCR13>3.0.CO;2-0
- Eilber F, Giuliano A, Eckardt J, et al (1987). Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol, 5, 21-6.
- Ferrari S, Bertoni F, Mercuri M, et al (2001). Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol, 12, 1145-50. https://doi.org/10.1023/A:1011636912674
- Ferrari S, Smeland S, Mercuri M, et al (2005). Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol, 23, 8845-52. https://doi.org/10.1200/JCO.2004.00.5785
- Fletcher CD (2006). The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology, 48, 3-12. https://doi.org/10.1111/j.1365-2559.2005.02284.x
- Gaffney R, Unni KK, Sim FH, et al (2006). Follow-up study of long-term survivors of osteosarcoma in the prechemotherapy era. Hum Pathol, 37, 1009-14. https://doi.org/10.1016/j.humpath.2006.02.022
- Goorin AM, Schwartzentruber DJ, Devidas M, et al (2003). Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol, 21, 1574-80. https://doi.org/10.1200/JCO.2003.08.165
- Hagleitner MM, Hoogerbrugge PM, van der Graaf WT, et al (2011). Age as prognostic factor in patients with osteosarcoma. Bone, 49, 1173-7. https://doi.org/10.1016/j.bone.2011.08.014
- Han J, Yong B, Luo C, et al (2012). High serum alkaline phosphatase cooperating with MMP-9 predicts metastasis and poor prognosis in patients with primary osteosarcoma in Southern China. World J Surgical Oncol, 10, 37. https://doi.org/10.1186/1477-7819-10-37
- Harris MB, Cantor AB, Goorin AM, et al (1995). Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol, 24, 87-92. https://doi.org/10.1002/mpo.2950240205
- Harris MB, Gieser P, Goorin AM, et al (1998). Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol, 16, 3641-8.
- Hegyi M, Semsei AF, Jakab Z, et al (2011). Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. Pediatr Blood Cancer, 57, 415-22. https://doi.org/10.1002/pbc.23172
- Hudson M, Jaffe MR, Jaffe N, et al (1990). Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol, 8, 1988-97.
- Jaffe N, Prudich J, Knapp J, et al (1983). Treatment of primary osteosarcoma with intra-arterial and intravenous high-dose methotrexate. J Clin Oncol, 1, 428-31.
- Jaffe N, Robertson R, Ayala A, et al (1985). Comparison of intraarterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol, 3, 1101-4.
- Lee JA, Kim MS, Kim DH, et al (2009). Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma. Pediatr Blood Cancer, 52, 340-5. https://doi.org/10.1002/pbc.21843
- Lewis IJ, Nooij MA, Whelan J, et al (2007). Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst, 99, 112-28. https://doi.org/10.1093/jnci/djk015
- Lewis IJ, Weeden S, Machin D, et al (2000). Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J Clin Oncol, 18, 4028-37.
- Lin F, Wang Q, Yu W, Tang L, et al (2011). Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol, 7, 270-5. https://doi.org/10.1111/j.1743-7563.2011.01406.x
- Link MP, Goorin AM, Miser AW, et al (1986). The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med, 314, 1600-6. https://doi.org/10.1056/NEJM198606193142502
- Mankin HJ, Hornicek FJ, Rosenberg AE, et al (2004). Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res, 429, 286-91. https://doi.org/10.1097/01.blo.0000145991.65770.e6
- Marcove RC, Mike V, Hajek JV, et al (1970). Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J Bone Joint Surg Am, 52, 411-23.
- Marina N, Bielack S, Whelan J, et al (2009). International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res, 152, 339-53. https://doi.org/10.1007/978-1-4419-0284-9_18
- Merkel KD, Gebhardt M, Springfield DS (2008). Rotationplasty as a reconstructive operation after tumor resection. Clin Orthop Relat Res, 270, 231-6.
- Meyers PA, Schwartz CL, Krailo M, et al (2005). Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol, 23, 2004-11. https://doi.org/10.1200/JCO.2005.06.031
- Meyers PA, Schwartz CL, Krailo MD, et al (2008). Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol, 26, 633-8. https://doi.org/10.1200/JCO.2008.14.0095
- Mirabello L, Troisi RJ, Savage SA (2009). International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer, 125, 229-34. https://doi.org/10.1002/ijc.24320
- Mirabello L, Troisi RJ, Savage SA (2009). Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer, 115, 1531-43. https://doi.org/10.1002/cncr.24121
- Ochs JJ, Freeman AI, Douglass HO Jr, et al (1978). cis- Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep, 62, 239-45.
- Rosen G (1993). An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma. Cancer Treat Res, 62, 49-54. https://doi.org/10.1007/978-1-4615-3518-8_9
- Smeland S, Bruland OS, Hjorth L, et al (2011). Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta orthopaedica, 82, 211-6. https://doi.org/10.3109/17453674.2011.566141
- Smith MA, Seibel NL, Altekruse SF, et al (2010). Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol, 28, 2625-34. https://doi.org/10.1200/JCO.2009.27.0421
- Souhami RL, Craft AW, Van der Eijken JW, et al (1997). Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet, 350, 911-7. https://doi.org/10.1016/S0140-6736(97)02307-6
- Stiller CA, Bielack SS, Jundt G, et al (2006). Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer, 42, 2124-35. https://doi.org/10.1016/j.ejca.2006.05.015
- van Dalen EC, van As JW, de Camargo B (2011). Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database Syst Rev, 5, 6325.
- Wiangnon S, Veerakul G, Nuchprayoon I, et al (2011). Childhood cancer incidence and survival 2003-2005, Thailand: study from the Thai Pediatric Oncology Group. Asian Pac J Cancer Prev, 12, 2215-20.
- Winkler K, Bielack S, Delling G, et al (1990). Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer, 66, 1703-10. https://doi.org/10.1002/1097-0142(19901015)66:8<1703::AID-CNCR2820660809>3.0.CO;2-V
- Wiromrat P, Jetsrisuparb A, Komvilaisak P, et al (2012). Incidence and survival rates among pediatric osteogenic sarcoma cases in Khon Kaen, Thailand, 1985-2010. Asian Pac J Cancer Prev, 13, 4281-4. https://doi.org/10.7314/APJCP.2012.13.9.4281
피인용 문헌
- Epidemiological Aspects of Osteosarcoma, Giant Cell Tumor and Chondrosarcoma Musculoskeletal Tumors - Experience of the National Rehabilitation Institute, Mexico City vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6451
- Association of Metastasis with Clinicopathological Data in Mexican Patients with Osteosarcoma, Giant Cell Tumor of Bone and Chondrosarcoma vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7689
- Continuous-infusion Ifosfamide and Doxorubicin Combination as Second-Line Chemotherapy for Recurrent or Refractory Osteosarcoma Patients in China: a Retrospective Study vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2391